HLA-G and B-cell chronic lymphocytic leukemia: Interestingly, the value of β2-microglobulin as an independent prognostic marker has not been extensively assessed in patients with CLL on CIT and targeted therapy, although in a previous study its predictive value for treatment-free survival was retained after adjusting for factors such as CD38 expression and IGHV mutation status [52].